Parexel International (ma) Corporation
Location
Massachusetts
Founded
1983-02-28
Website
Risk Signals
455 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Parexel International (ma) Corporation
Live alerts from global media, monitored by Business Radar
2023-08-16 (appliedclinicaltrialsonline.com)
Parexel and Partex Announce Alliance Leveraging Artificial Intelligence and Big Data
Clinical trial execution by the Partex group of companies will be managed by Parexel as the preferred CRO provider and parties will collaborate through the Partex-validated AI platform.
Read more
2020-05-20 (globenewswire.com)
Parexel Launches New #KeepingPatientsFirst Integrated Research Platform Powered by Microsoft Azure Providing Rapid Access to Critical New COVID-19 Data
Parexel’s leading Real-World Evidence expertise combined with Microsoft’s innovative cloud technology will support physicians and researchers in better understanding and adjusting treatment in real-time
Read more
2010-02-19 (nature.com)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Improving R&D productivity is crucial to ensuring the future viability of the pharmaceutical industry and advances in health care. This article presents a detailed analysis, based on comprehensive, recent, industry-wide data, to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity, and proposes strategies that could have the most substantial impact in enhancing R&D productivity. The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs.
Read more